Asset

ADINTREVIMAB

Invivyd Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04859517phase2_3terminated2021-04-272022-11-04Invivyd, Inc.Evaluation of ADG20 for the Prevention of COVID-19
NCT04805671phase2_3terminated2021-07-262022-02-10Invivyd, Inc.Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)